سال 24، شماره 95 - ( 7-1404 )
سال 24 شماره 95 صفحات 59-45 |
برگشت به فهرست نسخه ها
Ethics code: IRB00003121
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Thi Thu Nguyen H, Kim Nguyen N, Thi Thu Dinh H, Vinh Trinh Q, Thi Nhu Nguyen Q, Thi Thanh Nguyen H, et al . Antidiabetic effects of Morus alba Linn leaf extract in a high-fat diet and streptozotocin-induced type 2 diabetic mouse model. J. Med. Plants 2025; 24 (95) :45-59
URL: http://jmp.ir/article-1-3774-fa.html
URL: http://jmp.ir/article-1-3774-fa.html
Antidiabetic effects of Morus alba Linn leaf extract in a high-fat diet and streptozotocin-induced type 2 diabetic mouse model. فصلنامه گياهان دارویی. 1404; 24 (95) :45-59
چکیده: (1045 مشاهده)
Background: The rising prevalence of diabetes mellitus underscores the need for safer therapeutic options, including natural products. Morus alba Linn leaf extract (MAE), a traditional remedy and the key component of the herbal product DIDALA, has been investigated for its potential antidiabetic properties. Objective: This study aimed to investigate the hypoglycemic and lipid-modulating effects of MAE in a type 2 diabetes (T2DM) experimental model induced by a high-fat diet (HFD) and streptozotocin (STZ) in mice. Methods: T2DM was induced in male Swiss mice by 8 weeks of an HFD followed by an intraperitoneal injection of STZ at 100 mg/kg. Diabetic mice were orally administered for 14 days with either a low dose MAE (0.8208 g/kg/day), a high dose MAE (2.4624 g/kg/day), or Gliclazide (80 mg/kg/day) as a positive control. Outcomes assessed included fasting blood glucose, lipid profiles (total cholesterol, LDL-cholesterol), liver and pancreatic malondialdehyde (MDA) as a marker of oxidative stress, and histological examination. Results: The low dose of MAE significantly reduced fasting blood glucose and improved lipid profile by lowering total cholesterol and LDL-cholesterol, with outcomes comparable to the Gliclazide group. It also reduced liver and pancreatic MDA levels, indicating decreased oxidative stress, and ameliorated histopathological alterations in the liver and pancreas. The high-dose MAE exerted less pronounced effects on glucose levels but still demonstrated some lipid and oxidative stress benefits. Conclusion: MAE, particularly at the lower dose, exhibits promising hypoglycemic and lipid-lowering effects in a HFD/STZ-induced T2DM mouse model, supporting its potential as a natural therapeutic candidate for diabetes management. Further studies should explore dose optimization, long-term efficacy, safety, and mechanisms of action.
نوع مطالعه: پژوهشی |
موضوع مقاله:
فارماكوگنوزی و فارماسيوتيكس
دریافت: 1403/8/19 | پذیرش: 1404/5/18 | انتشار: 1404/7/10
دریافت: 1403/8/19 | پذیرش: 1404/5/18 | انتشار: 1404/7/10
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
